每周股票复盘：毕得医药（688073）调整回购价格上限并推进股份回购

Core Viewpoint - Bid Pharma (688073) has seen a significant increase in stock price, closing at 55.8 RMB, up 8.64% from the previous week, indicating positive market sentiment and potential growth opportunities [1] Company Announcements Summary - Bid Pharma has announced a share buyback plan, with the purpose of employee stock ownership plans or equity incentives [1] - As of June 30, 2025, the company has repurchased a total of 2,072,148 shares, representing 2.28% of its total share capital [1] - The company has adjusted the upper limit of its buyback price to not exceed 71.44 RMB per share, down from the previous limit of 72.30 RMB per share [2] - The buyback plan was first disclosed on February 8, 2025, and is set to be implemented from February 24, 2025, to August 23, 2025, with an expected buyback amount between 50 million to 100 million RMB [2] - The total amount spent on repurchases so far is approximately 94,147,819.45 RMB, with actual repurchase prices ranging from 37.47 RMB to 53.30 RMB per share [2]